Andrea Diaz-Tejedor

Ms. Andrea Diaz-Tejedor

Centro de Investigación del Cáncer-IBMCC (CSIC-Universidad de Salamanca), Complejo Asistencial Universitario de Salamanca-IBSAL, 37007 Salamanca, Spain
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ADAndrea Diaz-Tejedor
Andrea Diaz-Tejedor
MLMauro Lorenzo
Mauro Lorenzo
Noemí PuigNoemí Puig
Noemí Puig
Ramon Garcia-SanzRamon Garcia-Sanz
Ramon Garcia-Sanz
María Victoria MateosMaría Victoria Mateos
María Victoria Mateos
TPTeresa Paíno
Teresa Paíno
Immunosuppression is a common feature of multiple myeloma (MM) patients and has been associated with disease evolution from its precursor stages. MM cells promote immunosuppressive effects due to both the secretion of soluble factors, which inhibit the function of immune effector cells, and the recruitment of immunosuppressive populations. Alterations in the expression of surface molecules are also responsible for immunosuppression. In this scenario, immunotherapy, as is the case of immunotherapeutic monoclonal antibodies (mAbs), aims to boost the immune system against tumor cells. In fact, mAbs exert part of their cytotoxic effects through different cellular and soluble immune components and, therefore, patients’ immunosuppressive status could reduce their efficacy. Here, we will expose the alterations observed in symptomatic MM, as compared to its precursor stages and healthy subjects, in the main immune populations, especially the inhibition of effector cells and the activation of immunosuppressive populations. Additionally, we will revise the mechanisms responsible for all these alterations, including the interplay between MM cells and immune cells and the interactions among immune cells themselves. We will also summarize the main mechanisms of action of the four mAbs approved so far for the treatment of MM. Finally, we will discuss the potential immune-stimulating effects of non-immunotherapeutic drugs, which could enhance the efficacy of immunotherapeutic treatments.

18 July 2019 in Haematologica
Verified
Journal Article
Closed access
EAEsperanza M Algarín
Esperanza M Algarín
ADAndrea Diaz-Tejedor
Andrea Diaz-Tejedor
PAPedro Mogollón Arroyo
Pedro Mogollón Arroyo
SHSusana Hernández-García
Susana Hernández-García
Luis Antonio Corchete SánchezLuis Antonio Corchete Sánchez
Luis Antonio Corchete Sánchez
Enrique M. OcioEnrique M. Ocio
Enrique M. Ocio

13 November 2019 in Cells
Verified
Journal Article
Open access
PDF file
PAPedro Mogollón Arroyo
Pedro Mogollón Arroyo
ADAndrea Diaz-Tejedor
Andrea Diaz-Tejedor
EAEsperanza M. Algarín
Esperanza M. Algarín
TPTeresa Paíno
Teresa Paíno
MGMercedes Garayoa
Mercedes Garayoa
Enrique M. OcioEnrique M. Ocio
Enrique M. Ocio
A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.

31 August 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
SHSusana Hernández-García
Susana Hernández-García
LSLaura San-Segundo
Laura San-Segundo
LGLorena González-Méndez
Lorena González-Méndez
Luis Antonio Corchete SánchezLuis Antonio Corchete Sánchez
Luis Antonio Corchete Sánchez
IMIrena Misiewicz-Krzeminska
Irena Misiewicz-Krzeminska
Enrique M. OcioEnrique M. Ocio
Enrique M. Ocio
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma patients. The aim of the work herein was to investigate the activity of filanesib in combination with pomalidomide plus dexamethasone backbone, and the mechanisms underlying the potential synergistic effect. The ability of filanesib to enhance the activity of pomalidomide plus dexamethasone was studied in several in vitro and in vivo models. Mechanisms of this synergistic combination were dissected by gene expression profiling, immunostaining, cell cycle and short interfering ribonucleic acid studies. Filanesib showed in vitro, ex vivo, and in vivo synergy with pomalidomide plus dexamethasone treatment. Importantly, the in vivo synergy observed in this combination was more evident in large, highly proliferative tumors, and was shown to be mediated by the impairment of mitosis transcriptional control, an increase in monopolar spindles, cell cycle arrest and the induction of apoptosis in cells in proliferative phases. In addition, the triple combination increased the activation of the proapoptotic protein BAX, which has previously been associated with sensitivity to filanesib, and could potentially be used as a predictive biomarker of response to this combination. Our results provide preclinical evidence for the potential benefit of the combination of filanesib with pomalidomide and dexamethasone, and supported the initiation of a recently activated trial being conducted by the Spanish Myeloma group which is investigating this combination in relapsed myeloma patients.

4 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
EAEsperanza M. Algarín
Esperanza M. Algarín
DQDalia Quwaider
Dalia Quwaider
FCFrancisco Jose Campos-Laborie
Francisco Jose Campos-Laborie
ADAndrea Diaz-Tejedor
Andrea Diaz-Tejedor
PAPedro Mogollón Arroyo
Pedro Mogollón Arroyo
MGMercedes Garayoa
Mercedes Garayoa
BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM). Interleukin 6, produced by mesenchymal stromal cells (MSCs), has been shown to modify the expression of anti-apoptotic proteins and their interaction with the pro-apoptotic BIM protein in MM cells. In this study, we assess the efficacy of S63845 and venetoclax in MM cells in direct co-culture with MSCs derived from MM patients (pMSCs) to identify additional mechanisms involved in the stroma-induced resistance to these agents. MicroRNAs miR-193b-3p and miR-21-5p emerged among the top deregulated miRNAs in myeloma cells when directly co-cultured with pMSCs, and we show their contribution to changes in MCL-1 and BCL-2 protein expression and in the activity of S63845 and venetoclax. Additionally, direct contact with pMSCs under S63845 and/or venetoclax treatment modifies myeloma cell dependence on different BCL-2 family anti-apoptotic proteins in relation to BIM, making myeloma cells more dependent on the non-targeted anti-apoptotic protein or BCL-XL. Finally, we show a potent effect of the combination of S63845 and venetoclax even in the presence of pMSCs, which supports this combinatorial approach for the treatment of MM.

24 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TPTeresa Paíno
Teresa Paíno
LGLorena González-Méndez
Lorena González-Méndez
LSLaura San-Segundo
Laura San-Segundo
Luis Antonio Corchete SánchezLuis Antonio Corchete Sánchez
Luis Antonio Corchete Sánchez
SHSusana Hernández-García
Susana Hernández-García
Enrique M. OcioEnrique M. Ocio
Enrique M. Ocio
Background: Proviral Insertion site for Moloney murine leukemia virus (PIM) kinases are overexpressed in hematologic malignancies, including multiple myeloma. Previous preclinical data from our group demonstrated the anti-myeloma effect of the pan-PIM kinase inhibitor PIM447. Methods: Based on those data, we evaluate here, by in vitro and in vivo studies, the activity of the triple combination of PIM447 + pomalidomide + dexamethasone (PIM-Pd) in multiple myeloma. Results: Our results show that the PIM-Pd combination exerts a potent anti-myeloma effect in vitro and in vivo, where it markedly delays tumor growth and prolongs survival of treated mice. Mechanism of action studies performed in vitro and on mice tumor samples suggest that the combination PIM-Pd inhibits protein translation processes through the convergent inhibition of c-Myc and mTORC1, which subsequently disrupts the function of eIF4E. Interestingly the MM pro-survival factor IRF4 is also downregulated after PIM-Pd treatment. As a whole, all these molecular changes would promote cell cycle arrest and deregulation of metabolic pathways, including glycolysis and lipid biosynthesis, leading to inhibition of myeloma cell proliferation. Conclusions: Altogether, our data support the clinical evaluation of the triple combination PIM-Pd for the treatment of patients with multiple myeloma.